BIO - Bio-Rad Laboratories, Inc.
| Previous Close | 378.88 |
| Open | 379.77 |
| Bid | 379.30 x 800 |
| Ask | 379.53 x 1400 |
| Day's Range | 378.07 - 382.49 |
| 52 Week Range | 233.18 - 391.22 |
| Volume | 64,781 |
| Avg. Volume | 227,941 |
| Market Cap | 11.3B |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | 30.28 |
| EPS (TTM) | 12.48 |
| Earnings Date | Feb 25, 2020 - Mar 01, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 441.25 |
- Simply Wall St.
Is Bio-Rad Laboratories, Inc.'s (NYSE:BIO) ROE Of 7.3% Concerning?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Business Wire
Bio-Rad Appoints Dara Grantham Wright Executive Vice President and Clinical Diagnostics Group President
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dara Grantham Wright as Executive Vice President and President of the Clinical Diagnostics Group, effective January 1, 2020. She takes the place of John Hertia who retired from this role on December 31, 2019. Ms. Grantham Wright will be responsible for providing global leadership and management of the overall strategy and business direction for the company’s Clinical Diagnostics Group global operations.
- Business Wire
Bio-Rad to Participate at the 38th Annual J.P. Morgan Healthcare Conference on January 13
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 11 AM (Pacific Time), at the Westin St. Francis Hotel, San Francisco, California.
- Zacks
Bio-Rad Gains on New Product Portfolio Despite Currency Woes
Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.
- Insider Monkey
Bio-Rad Laboratories, Inc. (BIO) vs. Top 20 Hedge Fund Stocks in 2019
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]
- Business Wire
The International Trade Commission Issues Final Decision Affirming 10X Genomics Infringement of Three of Bio-Rad’s Patents
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the International Trade Commission (ITC) affirmed the Administrative Law Judge’s finding that 10X Genomics infringed three of Bio-Rad’s patents.
- Business Wire
Bio-Rad Makes Progress Recovering from Recent Ransomware Attack
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) a global leader of life science research and clinical diagnostic products, today announced that the Company is making good progress recovering from a ransomware attack that was detected on Bio-Rad’s network on December 5, 2019. Once the malicious software was detected, Bio-Rad immediately took certain systems offline as part of its comprehensive response to contain the activity.
- Simply Wall St.
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Today we're going to take a look at the well-established Bio-Rad Laboratories, Inc. (NYSE:BIO). The company's stock...
- Thomson Reuters StreetEvents
Edited Transcript of BIO earnings conference call or presentation 1-Aug-19 9:00pm GMT
Q2 2019 Bio Rad Laboratories Inc Earnings Call
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Bio-Rad Laboratories, Inc. (BIO)
We can judge whether Bio-Rad Laboratories, Inc. (NYSE:BIO) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
- Zacks
Bio-Rad's Blood Typing Market Growth Strong on New Products
Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.
- Thomson Reuters StreetEvents
Edited Transcript of BIO earnings conference call or presentation 31-Oct-19 9:00pm GMT
Q3 2019 Bio Rad Laboratories Inc Earnings Call
- Simply Wall St.
Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Zacks
Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth
Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.
- Business Wire
Bio-Rad Reports Third-Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2019.
- Insider Monkey
This Hedge Fund Can Still Deliver Double Digit Returns: Here Are Its Top Picks
Tamarack Capital Management was founded by Justin John Ferayorni, who remained the fund’s Chief Investment Officer and Portfolio Manager. Mr. Ferayorni holds A.B. degree in Chemistry from Princeton University, as well as Chartered Financial Analyst designation. Prior to founding Tamarack Capital Management, he worked as Healthcare Analyst and Portfolio Manager. He also held a position of […]
- Zacks
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GuruFocus.com
5 Companies Hit 52-Week Highs
PPG among companies that reach annual milestone Continue reading...
- Business Wire
Bio-Rad to Report Third-Quarter 2019 Financial Results Thursday, October 31, 2019
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2019 on Thursday, October 31, 2019, following the close of the market.
- InvestorPlace
5 Stocks to Buy in the Mighty Middle
This is now the second time in roughly a year that actress Elizabeth Banks -- and the marketing team at State Street -- has told us to pay attention to the "middle." And yet, most of us continue to ignore her siren call about mid-cap stocks, which is a huge shame because she happens to be right. Mid-cap stocks and ETFs like the SPDR S&P MidCap 400 ETF (NYSEArca:MDY) are darn good for your portfolio.It turns out that mid-cap stocks fall right in the sweet spot for long-term growth. They aren't too big that their best days are behind them. At the same time, they are just big enough to survive economic duress and downturns. Many of the brands and services we use day-to-day are actually performed by mid-cap companies. Add in their higher rates of dividend growth and you have a recipe for long-term success.Just how much success? Mid-cap stocks, roughly defined as companies between $2 billion and $10 billion in market capitalization, have managed to produce an extra 753% cumulative return over small-caps since the 1990s. And they've done so with less overall volatility. Meanwhile, mid-caps have managed to outperform their larger rivals as well over that time period.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Hot Stocks Staging Huge Reversals The reality is, mid-cap stocks offer the perfect blend of growth and stability that many investors need. We should listen to Banks' advice and head towards the middle. Mid-caps really are that great for our portfolio's health. With that, here are five mid-cap stocks that could be great additions to your investments. Mighty Mid-Cap Stocks to Buy: Zebra Technologies (ZBRA)There's a good chance that you've never heard of Zebra Technologies (NASDAQ:ZBRA). But I can guarantee if you've ever been shopping at some point in your life -- either online or in-store -- your purchase has interacted with their products.Source: The DEMO Conference via FlickrZBRA makes all sorts of barcode scanners, printers, RFID labels, software, and other inventory tracking gear. All of their products are a must-have for retailers looking to ship and stock their shelves. And even more so in the world of omnichannel retailing.With consumers wanting their goods when and how they want them, inventory tracking has become even more important. For Zebra, that's meant a surge in sales. Year-over-year, ZBRA managed to see an 8.9% jump in revenues for its latest quarter. This continues a long trend of higher sales. Even better is a shift towards more high-margin software that has helped boost profits by 75% year-over-year.But e-commerce and omnichannel retail sales aren't the only way Zebra is winning. The firm's products are quickly being demanded by hospitals, food producers and other industries as regulations and safety concerns require intense tracking of goods. The addition of IoT products to its mix is also helping. With that, ZBRA has plenty of room to grow over the long haul.With plenty of cash flows, a new $1 billion buyback program and growth on the horizon, ZBRA is a wonderful mid-cap stock to buy today. Paycom (PAYC)Cloud computing, software as a service (SaaS) and other off-site applications have taken the world by storm. And while there are plenty of larger firms dominating the space, there are many mid-cap stocks winning in the cloud. Case in point: Paycom (NASDAQ:PAYC).PAYC is a perfect example of what the cloud is really good for: automating and performing boring tasks for customers. In this case, it's a variety of human resources functions. Through its suite of applications, Paycom allows HR departments to hire, develop, pay and manage benefits for employees. On the flip side, employees can use PAYC's apps to request time off, enroll in retirement plans, fill in timesheets, etc. Often these tasks can be done via smartphone.The key for PAYC, unlike rival Workday (NASDAQ:WDAY), is that the firm has moved down the ladder in terms of client size. We're talking mom-and-pop businesses to medium-sized firms with a couple hundred employees. This focus has allowed Paycom some great retention rates and growth.Last quarter, PAYC realized a big 31% jump in revenues as it continues to hook more customers and move existing ones into other products. And unlike many smaller cloud stocks, Paycom is profitable -- realizing a 37% jump in EPS year-over-year. * 10 Tech Stocks to Buy Now for 2025 With plenty of ways to add growth and additional customers, PAYC is a prime example of how mid-cap stocks can be used to fuel growth in a portfolio. National Retail Properties (NNN)Sure, many malls across the country are dying a slow death. But not all retail real estate is suffering. Just take a look at your local Taco Bell, bank branch, or Jiffy Lube. These free-standing buildings offer a huge opportunity for mid-cap stock investors -- especially when they are owned by National Retail Properties (NYSE:NNN).NNN owns a huge portfolio of these free-standing buildings and centers -- nearly 3045 to be exact. The win for NNN and its shareholders is that these properties fall under the guise of triple-net leased properties. Here, the tenant is responsible for the payment of taxes, maintenance and other fees associated with renting the property. For landlords, the removal of these extra costs results in a much bigger rent check and profit margin per property. And with its size, National Retail has been able to feast on this fact throughout its history. With its better cash flows, the firm has one of the longest streaks of dividend growth -- 29 years straight -- among all REITs. Currently, NNN yields a healthy 3.6%.The future looks bright for NNN. The vast bulk of its tenants include LA Fitness gyms, 7-Eleven, and Wendy's (NYSE:WEN) franchises. We're talking about internet-proof retail operations. This will continue to boost NNN's occupancy rates and keep the cash flowing towards investors. Bio-Rad Laboratories (BIO)During the gold rush, the people who made the most money weren't the miners themselves, but the stores that provided all the picks and shovels. Today's gold rush could be biotech and healthcare researchers. One of the best mid-cap stocks providing the "picks and shovels" happens to be Bio-Rad Laboratories (NYSE:BIO).BIO may not be as well known to investors as rivals Thermo-Fisher (NYSE:TMO) or Illumina (NASDAQ:ILMN), but its products do find their way into a variety of both public and private research labs. This includes everything from instruments costing tens of thousands of dollars to one-time use consumables and reagents. The combination of products, both advanced and basic, has continued to benefit BIO over its history. Last year, sales at the firm rose 5% as more drug and universities plowed some hefty dollars into research.And that fact doesn't show any signs of slowing. Continued life sciences spending is expected to surge over the next few years by an annual rate of 6% as scientists tackle hard to treat illnesses and diseases. * Buy These 7 Mid-Cap Stocks to Make a Profit This will only help boost BIO's strong pace of growth further. Add in recent wins on the margins front and product additions to its digital life sciences/software segments, and you're looking a great mid-cap stock to own for the long haul. Domino's Pizza (DPZ)Is it a pizza joint or the latest tech start-up full of innovation? For Domino's Pizza (NYSE:DPZ), its looking more like the latter than the former. DPZ has transformed itself over the last few years as it has taken tech spending to a whole new level. The restaurant was one of the first in the sector to offer online ordering. Since that day in 2007, DPZ hasn't looked back.These days, Domino's offers a whole suite of digital tools to make ordering its food easier. This builds on its AnyWare technology. AnyWare allows customers to order a pizza from 15 different methods, including their phone, from their car via Ford (NYSE:F) Sync, Google (NASDAQ:GOOG, NASDAQ:GOOGL) Home devices and even Slack (NASDAQ:WORK) while at the office. And it continues to add more capabilities to the platform. Moreover, it has rolled out new apps including a one-click system that purchases a customer's normal pizza order in 10 seconds.As a result, DPZ has seen sales surge with digital ordering now making up roughly two-thirds of its sales.Now rivals are starting to move into DPZ's territory with new online ordering and applications. However, DPZ continues to innovate and first-mover status still has it coming out ahead in the pizza wars.For investors seeking mid-cap stocks, Domino's could be a great "tech" play.At the time of writing, Aaron Levitt did not hold a position in any stock mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Hot Stocks Staging Huge Reversals * 7 Under-The-Radar Growth Stocks That Could Benefit New Investors * 5 Excellent High-Yield Dividend Stocks to Buy The post 5 Stocks to Buy in the Mighty Middle appeared first on InvestorPlace.
- Insider Monkey
Here’s What Hedge Funds Think About Bio-Rad Laboratories, Inc. (BIO)
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
- Zacks
LabCorp (LH) Names Two Leaders for Major Business Wings
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
- Zacks
Bruker To Buy Freiberg Instruments' Magnettech EPR Business
The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.
- Zacks
Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
- American City Business Journals
It's not just Google: 'Fierce' competition for tech talent is pushing median salaries past $200K at many Silicon Valley companies
Compensation experts say the region's labor market is at an inflection point as demand for top tech talent drives salaries ever-higher. Here's what that means for the median paycheck at companies like Netflix, Facebook, Oracle, Intel and Cisco.
